Catherine Moukheibir joined our board of directors in April 2019. Ms. Moukheibir most recently served as the senior adviser for finance and member of the executive board at Innate Pharma. Prior to that, Ms. Moukheibir was the chief financial officer for Movetis NV from 2008 until its acquisition by Shire Plc in 2010. Ms. Moukheiber previously served as the director of capital markets for Zeltia Group S. A. Ms. Moukheibir’s current company board membership includes MedDay Pharmaceuticals, Orphazyme A/S, Genkyotex, and Zealand Pharma A/S. Ms. Moukheibir holds an M.A. in economics and an MBA from Yale University.